Rare Diseases Symptoms Automatic Extraction
Home
A random Abstract
Our Project
Our Team
BRAF--a new player in hematological neoplasms.
[erdheim-chester disease]
BRAF
oncogenic
kinase
has
become
a
target
for
specific
therapy
in
oncology
.
Genetic
characterization
of
a
predominant
V
600
E
mutation
in
melanoma
,
thyroid
cancer
,
and
other
tumors
became
a
focus
for
developing
specific
inhibitors
,
such
as
vemurafenib
or
dabrafenib
.
Our
knowledge
regarding
the
role
of
mutated
BRAF
in
hematological
malignancies
has
grown
quickly
as
a
result
of
new
genetic
techniques
such
as
next
-generation
sequencing
.
This
review
summarizes
current
knowledge
regarding
the
role
of
BRAF
in
lymphoid
and
myeloid
neoplasms
,
with
a
focus
on
hairy-cell
leukemia
,
Langerhans
cell
histiocytosis
,
and
Erdheim-
Chester
disease
.
